1. Stem Cell/Wnt
  2. YAP
  3. LC-TEAD01

LC-TEAD01 is a potent covalent transcription enhancer-associated domain (TEAD) inhibitor with an IC50 of 116 nM and a Ki of 0.132 μM. LC-TEAD01 disrupts the TEAD-YAP interaction and inhibits TEAD-dependent transcriptional activity. LC-TEAD01 suppresses the proliferation of NF2-deficient cancer cells. LC-TEAD01 inhibits tumor growth in NF2-deficient xenograft models. LC-TEAD01 can be used in studies related to NF2-deficient malignant pleural mesothelioma.

For research use only. We do not sell to patients.

LC-TEAD01

LC-TEAD01 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All YAP Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LC-TEAD01 is a potent covalent transcription enhancer-associated domain (TEAD) inhibitor with an IC50 of 116 nM and a Ki of 0.132 μM. LC-TEAD01 disrupts the TEAD-YAP interaction and inhibits TEAD-dependent transcriptional activity. LC-TEAD01 suppresses the proliferation of NF2-deficient cancer cells. LC-TEAD01 inhibits tumor growth in NF2-deficient xenograft models. LC-TEAD01 can be used in studies related to NF2-deficient malignant pleural mesothelioma[1].

IC50 & Target[1]

TEAD

116 nM (IC50)

TEAD

0.132 μM (Ki)

In Vitro

LC-TEAD01 (1 h) binds to the lipid pocket of purified TEAD1 protein with an IC50 of 116 nM[1].
LC-TEAD01 inhibits the autopalmitoylation of purified TEAD1 protein, with an IC50 value of 220 nM[1].
LC-TEAD01 disrupts the interaction between purified TEAD1 protein and YAP peptide, with an IC50 of 48.29 nM, and this effect depends on binding to Cys359[1].
LC-TEAD01 (0.0001-100 μM; 5 days) potently and selectively inhibits the proliferation of NF2-deficient NCI-H226 mesothelioma cells, with an IC50 of 0.618 μM[1].
LC-TEAD01 (0-30 μM) dose-dependently disrupts the TEAD1-YAP protein-protein interaction in HEK-293T cells overexpressing TEAD1 and YAP proteins[1].
LC-TEAD01 (0-3 μM) dose-dependently inhibits TEAD-dependent transcriptional activity in HEK-293T cells transfected with a TEAD-responsive luciferase reporter gene[1].
LC-TEAD01 (0.625-2.5 μM) reduces the mRNA expression levels of TEAD downstream target genes CTGF and CYR61 in NCI-H226 cells in a dose-dependent manner[1].
LC-TEAD01 (0.625-10 μM) dose-dependently inhibits the protein expression of CYR61, a downstream target gene of TEAD, in NCI-H226 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: NCI-H226 (NF2-deficient mesothelioma), NCI-H2452 (NF2 wild-type mesothelioma), HEK-293T
Concentration: 0.0001, 0.01, 1, 100 μM
Incubation Time: 5 days
Result: Inhibited proliferation of NCI-H226 cells with an IC50 of 0.618 μM.
Inhibited proliferation of NCI-H2452 cells with an IC50 of 9.839 μM.
Showed minimal activity against HEK-293T cells (IC50 > 15 μM).
Exhibited a selectivity ratio between NCI-H2452 and NCI-H226 cells exceeding 17-fold.
Parmacokinetics
Species Dose Route Cmax AUC0-∞
Rat[1] 10 mg/kg p.o. 81.4 ng/mL 78.8 ng·h/mL
Rat[1] 50 mg/kg i.p. 6207 ng/mL 4291 ng·h/mL
In Vivo

LC-TEAD01 (30-50 mg/kg; i.p.; daily; 21 days) exhibits potent, well-tolerated antitumor activity in NF2-deficient NCI-H226 mesothelioma xenografts, reducing tumor growth, proliferation, and TEAD-dependent gene expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c Nude (male, 6 weeks old, subcutaneously injected with 2 × 106 NCI-H226 NF2-deficient malignant pleural mesothelioma cells)[1]
Dosage: 30 mg/kg; 50 mg/kg
Administration: i.p.; daily; 21 days
Result: Induced marked tumor growth inhibition relative to vehicle control.
Did not cause significant body weight loss.
Reduced tumor cellularity, increased intratumoral vacuolization, and decreased Ki67-positive cell proportions in treated tumors.
Significantly downregulated TEAD downstream target gene CYR61 mRNA and protein levels in tumor tissues.
Molecular Weight

308.36

Formula

C13H16N4O3S

SMILES

C=CS(=O)(NCC1=CN(N=N1)C2=CC=C(C=C2)OCC)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LC-TEAD01
Cat. No.:
HY-183728
Quantity:
MCE Japan Authorized Agent: